/
AVTR
$9.99-$0.04 (-0.45%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$7.0B
683M shares
52-week range
$7.27 – $15.93
31% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-26.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.86B | $6.04B | $6.39B | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B |
| Cost of revenue | $4.04B | $4.12B | $4.31B | $4.88B | $4.91B | $4.60B | $4.50B | $4.41B |
| Gross profit | $1.82B | $1.92B | $2.08B | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B |
| Gross margin | 31.0% | 31.8% | 32.5% | 33.9% | 34.6% | 33.9% | 33.6% | 32.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $413.5M | $551.8M | $706.8M | $972.2M | $1.13B | $696.4M | $1.08B | −$246.2M |
| EBITDA | $814.6M | $879.5M | $765.3M | $1.35B | $1.52B | $1.10B | $1.48B | $138.7M |
| Net income | −$86.9M | $37.8M | $116.6M | $572.6M | $686.5M | $321.1M | $711.5M | −$530.2M |
| Net margin | -1.5% | 0.6% | 1.8% | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% |
| EPS (diluted) | -0.72 | -0.84 | 0.09 | 0.85 | 1.01 | 0.47 | 1.04 | -0.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.5B | $0.79 | $0.78–$0.80 | 9 |
| 2027 | $6.6B | $0.85 | $0.81–$0.89 | 9 |
| 2028 | $6.9B | $0.91 | $0.80–$1.08 | 3 |
| 2029 | $7.1B | $0.98 | $0.98–$1.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$27.30
Price
$9.98
Implied upside
+173%
Peer comparison
Avantor, Inc.
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
www.avantorsciences.com- Employees
- 13,500
- IPO / List date
- May 17, 2019
- HQ
- RADNOR, PA
Held by traders on TradeandTell
No one on the platform currently holds AVTR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 1,651,100 | $20.6M |
| Bridgewater Associatesas of 2026-03-31 | 128,209 | $1.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AVTR yet.
